Key facts
- It has raised $10.6M; the latest was Later Stage VC ($5.8M) in Sep 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for ARTCLINE
- ·The full record, as it builds
Funding rounds
No funding rounds for ARTCLINE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ARTCLINE
Operator of an immune cell-based extracorporeal therapy intended for treating sepsis. The company provides allogeneic immune cell therapy, removal of inflammatory substances, and production of immunological messengers, enabling healthcare providers to treat sepsis, reduce mortality rates, and improve patient outcomes in intensive care units.
- Sector
- Healthcare
- HQ
- Rostock, Germany
- Founded
- 2007
- Employees
- 17
- Website
- artcline.de/
- Ownership
- Privately Held (backing)
ARTCLINE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ARTCLINE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ARTCLINE in its N-PORT filings yet. We sweep new filings monthly.